Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices.
Sumeet S VaikunthSwethika SundaravelJoshua SaefJuan Ortega-LegaspiPublished in: Current heart failure reports (2023)
After highlighting the increasing prevalence and a few of the unique potential causes, including the concept of early senescence, this review begins with novel medical management strategies such as the angiotensin II receptor blocker and neprilysin inhibitors and sodium glucose cotransporter-2 inhibitors. Then, it addresses the latest applications of percutaneous techniques like implantable hemodynamic monitoring, transcatheter pulmonary and aortic valve replacement, and mitral clips. Cardiac resynchronization therapy and novel lymphatic system imaging and intervention are then described. Finally, the use of mechanical support devices, temporary and durable, is discussed as well as heart and combined heart and liver transplantation. There have been recent exciting advances in the strategies used to manage adult congenital heart disease patients with heart failure. As this population continues to grow, it is likely we will see further rapid evolution in this field.
Keyphrases
- congenital heart disease
- heart failure
- cardiac resynchronization therapy
- angiotensin ii
- aortic valve replacement
- left ventricular
- aortic stenosis
- angiotensin converting enzyme
- transcatheter aortic valve implantation
- aortic valve
- vascular smooth muscle cells
- mitral valve
- transcatheter aortic valve replacement
- atrial fibrillation
- ejection fraction
- randomized controlled trial
- high resolution
- healthcare
- left atrial
- pulmonary hypertension
- minimally invasive
- acute heart failure
- lymph node
- dna damage
- ultrasound guided
- childhood cancer
- human health
- risk assessment
- climate change
- stress induced
- mass spectrometry
- photodynamic therapy
- oxidative stress